DrugPatentWatch Database Preview
Litigation Details for Takeda Pharmaceuticals USA Inc. v. Par Pharmaceutical Companies Inc. (D. Del. 2013)
» See Plans and Pricing
Takeda Pharmaceuticals USA Inc. v. Par Pharmaceutical Companies Inc. (D. Del. 2013)
| Docket | Start Trial | Date Filed | 2013-08-30 |
| Court | District Court, D. Delaware | Date Terminated | 2016-01-11 |
| Cause | 35:271 Patent Infringement | Assigned To | Sue Lewis Robinson |
| Jury Demand | None | Referred To | |
| Parties | PAR PHARMACEUTICAL INC. | ||
| Patents | 7,601,758; 7,619,004; 7,820,681; 7,906,519; 7,915,269; 7,935,731; 7,964,647; 7,964,648; 7,981,938; 8,093,296; 8,093,297; 8,093,298; 8,097,655; 8,415,395; 8,415,396; 8,440,721; 8,440,722 | ||
| Attorneys | Bradford C. Frese | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Takeda Pharmaceuticals USA Inc. v. Par Pharmaceutical Companies Inc.
The small molecule drug covered by the patents cited in this case is Start Trial .
Details for Takeda Pharmaceuticals USA Inc. v. Par Pharmaceutical Companies Inc. (D. Del. 2013)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2014-10-09 | 106 | infringement of U.S. Patent Nos. 7,619,004 (“the ’004 patent”); 7,601,758 (“the ’758 patent”); 7,820,681 (“…(“the ’681 patent”); 7,915,269 (“the ’269 patent”); 7,964,647 (“the ’647 patent”); 7,964,648 (“the ’648…648 patent”); 7,981,938 (“the ’938 patent”); 8,093,296 (“the ’296 patent”); 8,093,297 (“the ’297 patent…8,097,655 (“the ’655 patent”); 8,415,395 (“the ’395 patent”); 8,415,396 (“the ’396 patent”); 8,440,721 (“the…“the ’721 patent”); and 8,440,722 (“the ’722 patent”) (collectively, “the Gout Patents”); will not infringe | External link to document | |
| 2015-06-01 | 196 | .S. Patent Nos. 7,619,004 ("the '004 patent"), 7,964,647 ("the '647 patent"…the '64 7 patent, claim 1 of the '938 patent, claims 1 and 13 of the '395 patent, and claim …,938 ("the '938 patent"), 8,415,395 ("the '395 patent"), and 8,415,396 (&…("the '396 patent") shall be construed consistent with the tenets of claim construction…construction required. Claim 1 of the '938 patent calls for administering 1.2 mgA oral colchicine | External link to document | |
| 2014-09-04 | 66 | Fourteen patents- U.S. Patent Nos. 7,619,004 ("the '004 patent"); 7,601,758 ("the…269 patent"); 7,964,647 ("the '647 patent"); 7,981,938 ("the '938 patent"…ex. 1 at~ 15) Five patents- U.S. Patent Nos. 7,906,519 ("the '519 patent"); 7,935,731 (…the '758 patent"); 7,820,681 ("the '681 patent"); 7,915,269 ("the '269…,296 ("the '296 patent"); 8,097,655 ("the '655 patent"); 8,415,395 (" | External link to document | |
| 2014-09-04 | 90 | Fourteen patents- U.S. Patent Nos. 7,619,004 ("the '004 patent"); 7,601,758 ("the…269 patent"); 7,964,647 ("the '647 patent"); 7,981,938 ("the '938 patent"…ex. 1 at~ 15) Five patents- U.S. Patent Nos. 7,906,519 ("the '519 patent"); 7,935,731 (…the '758 patent"); 7,820,681 ("the '681 patent"); 7,915,269 ("the '269…,296 ("the '296 patent"); 8,097,655 ("the '655 patent"); 8,415,395 (" | External link to document | |
| 2014-09-04 | 91 | G. United States Patent Number 7,601,758 (“the ‘758 Patent”), entitled “METHODS FOR CONCOMITANT…States Patent Nos. 7,906,519; 7,935,731; 8,093,298; 7,964,648; 8,093,297; 7,619,004; 7,601,758; 7,820,681… This is an action for patent infringement under the Food and Drug and Patent Laws of the United States… A. United Sates Patent Number 7,906,519 (“the ‘519 Patent”), entitled “METHODS FOR CONCOMITANT… B. United States Patent Number 7,935,731 (“the ‘731 Patent”), entitled “METHODS FOR CONCOMITANT | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
